371 related articles for article (PubMed ID: 33014289)
1. Advances in epidermal growth factor receptor specific immunotherapy: lessons to be learned from armed antibodies.
Biteghe FAN; Mungra N; Chalomie NET; Ndong JC; Engohang-Ndong J; Vignaux G; Padayachee E; Naran K; Barth S
Oncotarget; 2020 Sep; 11(38):3531-3557. PubMed ID: 33014289
[TBL] [Abstract][Full Text] [Related]
2. EGFR targeting for cancer therapy: Pharmacology and immunoconjugates with drugs and nanoparticles.
Santos EDS; Nogueira KAB; Fernandes LCC; Martins JRP; Reis AVF; Neto JBV; Júnior IJDS; Pessoa C; Petrilli R; Eloy JO
Int J Pharm; 2021 Jan; 592():120082. PubMed ID: 33188892
[TBL] [Abstract][Full Text] [Related]
3. Targeted human cytolytic fusion proteins at the cutting edge: harnessing the apoptosis-inducing properties of human enzymes for the selective elimination of tumor cells.
Mungra N; Jordaan S; Hlongwane P; Naran K; Chetty S; Barth S
Oncotarget; 2019 Jan; 10(8):897-915. PubMed ID: 30783518
[TBL] [Abstract][Full Text] [Related]
4. Targeting epidermal growth factor receptor in solid tumors: critical evaluation of the biological importance of therapeutic monoclonal antibodies.
Gialeli Ch; Kletsas D; Mavroudis D; Kalofonos HP; Tzanakakis GN; Karamanos NK
Curr Med Chem; 2009; 16(29):3797-804. PubMed ID: 19747140
[TBL] [Abstract][Full Text] [Related]
5. The efficient elimination of solid tumor cells by EGFR-specific and HER2-specific scFv-SNAP fusion proteins conjugated to benzylguanine-modified auristatin F.
Woitok M; Klose D; Niesen J; Richter W; Abbas M; Stein C; Fendel R; Bialon M; Püttmann C; Fischer R; Barth S; Kolberg K
Cancer Lett; 2016 Oct; 381(2):323-30. PubMed ID: 27502168
[TBL] [Abstract][Full Text] [Related]
6. Induction of anti-EGFR immune response with mimotopes identified from a phage display peptide library by panitumumab.
Wang A; Cui M; Qu H; Di J; Wang Z; Xing J; Wu F; Wu W; Wang X; Shen L; Jiang B; Su X
Oncotarget; 2016 Nov; 7(46):75293-75306. PubMed ID: 27659529
[TBL] [Abstract][Full Text] [Related]
7. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
Harding J; Burtness B
Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
[TBL] [Abstract][Full Text] [Related]
8. Immunotoxins in cancer therapy: Review and update.
Akbari B; Farajnia S; Ahdi Khosroshahi S; Safari F; Yousefi M; Dariushnejad H; Rahbarnia L
Int Rev Immunol; 2017 Jul; 36(4):207-219. PubMed ID: 28282218
[TBL] [Abstract][Full Text] [Related]
9. Targeted therapy of solid tumors by monoclonal antibody specific to epidermal growth factor receptor.
Baradaran B; Majidi J; Farajnia S; Barar J; Omidi Y
Hum Antibodies; 2014; 23(1-2):13-20. PubMed ID: 25812698
[TBL] [Abstract][Full Text] [Related]
10. Anti-CD3 x anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model.
Reusch U; Sundaram M; Davol PA; Olson SD; Davis JB; Demel K; Nissim J; Rathore R; Liu PY; Lum LG
Clin Cancer Res; 2006 Jan; 12(1):183-90. PubMed ID: 16397041
[TBL] [Abstract][Full Text] [Related]
11. Genetically engineered monoclonal antibodies for direct anti-neoplastic treatment and cancer cell specific delivery of chemotherapeutic agents.
Bodey B; Bodey B; Siegel SE; Kaiser HE
Curr Pharm Des; 2000 Feb; 6(3):261-76. PubMed ID: 10637379
[TBL] [Abstract][Full Text] [Related]
12. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
[TBL] [Abstract][Full Text] [Related]
13. Vaccination with cetuximab mimotopes and biological properties of induced anti-epidermal growth factor receptor antibodies.
Riemer AB; Kurz H; Klinger M; Scheiner O; Zielinski CC; Jensen-Jarolim E
J Natl Cancer Inst; 2005 Nov; 97(22):1663-70. PubMed ID: 16288119
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor receptor inhibition strategies in oncology.
Harari PM
Endocr Relat Cancer; 2004 Dec; 11(4):689-708. PubMed ID: 15613446
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of tumor uptake and therapeutic efficacy of EGFR-targeted antibody cetuximab and antibody-drug conjugates by cholesterol sequestration.
Chen Y; Liu G; Guo L; Wang H; Fu Y; Luo Y
Int J Cancer; 2015 Jan; 136(1):182-94. PubMed ID: 24798787
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor targeting in cancer: a review of trends and strategies.
Yewale C; Baradia D; Vhora I; Patil S; Misra A
Biomaterials; 2013 Nov; 34(34):8690-707. PubMed ID: 23953842
[TBL] [Abstract][Full Text] [Related]
17. 177Lu-labeled antibodies for EGFR-targeted SPECT/CT imaging and radioimmunotherapy in a preclinical head and neck carcinoma model.
Liu Z; Ma T; Liu H; Jin Z; Sun X; Zhao H; Shi J; Jia B; Li F; Wang F
Mol Pharm; 2014 Mar; 11(3):800-7. PubMed ID: 24472064
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and Characterization of Cetuximab-Docetaxel and Panitumumab-Docetaxel Antibody-Drug Conjugates for EGFR-Overexpressing Cancer Therapy.
Glatt DM; Beckford Vera DR; Prabhu SS; Mumper RJ; Luft JC; Benhabbour SR; Parrott MC
Mol Pharm; 2018 Nov; 15(11):5089-5102. PubMed ID: 30226780
[TBL] [Abstract][Full Text] [Related]
19. A novel fully-human cytolytic fusion protein based on granzyme B shows in vitro cytotoxicity and ex vivo binding to solid tumors overexpressing the epidermal growth factor receptor.
Niesen J; Hehmann-Titt G; Woitok M; Fendel R; Barth S; Fischer R; Stein C
Cancer Lett; 2016 May; 374(2):229-40. PubMed ID: 26912070
[TBL] [Abstract][Full Text] [Related]
20. Plant-made immunotoxin building blocks: A roadmap for producing therapeutic antibody-toxin fusions.
Knödler M; Buyel JF
Biotechnol Adv; 2021; 47():107683. PubMed ID: 33373687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
